openPR Logo
Press release

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Therapeutics - Pipeline Analysis 2018

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome)

Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a progressive disorder that primarily affects brain and spinal cord (central nervous system). People with MPS III generally do not display features at birth, but they begin to show signs and symptoms of this disorder during early childhood. Affected children often initially have delayed speech and behaviour problems.

Download the sample report @

In later stages of this disorder, people with MPS III may develop seizures and movement disorders. Patients with MPS III are also known to have short stature, joint stiffness, or mild dysostosis multiplex. Affected individuals often experience chronic diarrhoea and recurrent upper respiratory and ear infections. People with MPS III may also have hearing loss and vision problems. MPS III is divided into four types; IIIA, IIIB, IIIC, and IIID, which are distinguished by their genetic cause.

Get the detailed analysis @

The drug candidates in MPS III pipeline include, but are not limited to, EGT-101, MPS IIIA (Sanfilippo A) Program and LYS-SAF302. Some companies having drugs in the MPS III pipeline are Esteve Pharmaceuticals S.A., Orchard Therapeutics Limited, Lysogene S.A. among others.

Make enquiry before purchase @

• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Therapeutics - Pipeline Analysis 2018 here

News-ID: 1721729 • Views: 566

More Releases for MPS

Modular Panelboard System (MPS) Market 2022 | Detailed Report
Global Modular Panelboard System (MPS) Market 2021-2027, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. An exclusive data offered in this report is collected by research and industry experts team. Download FREE Sample Report @ The report
Managed Print Services (MPS) Market Experience A Tremendous growth in future
HTF MI recently introduced Global Managed Print Services (MPS) Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Xerox Corporation, HP, Canon, Ricoh, Lexmark, Konica Minolta Inc.,
Managed Print Services (MPS) Industry Is Moving Fast | Opportunities & Challenge …
The Report provides a basic overview of the Managed Print Services (MPS) Market including definitions, classifications, applications and chain structure. The Managed Print Services (MPS) Industry analysis is provided for the international market including development history, competitive landscape analysis, and major regional development status. The detailed report of Global Managed Print Services (MPS) Market evaluated by skilled experts is segmented into Application and Product. The Global Managed Print Services (MPS) Market
Global Managed Print Services (MPS) Market - Key Trends, Challenges and Standard …
Qyresearchreports include new market research report Global Managed Print Services (MPS) Market Size,Status and Forecast 2025 to its huge collection of research reports. The comprehensive report on the global market for Managed Print Services (MPS) presents an insightful peek into it after primary interviews, in-house expert panel reviews, and in-depth secondary research. It sets out with a basic description of Managed Print Services (MPS) and its market overview. It then moves
ROTOCONTROL Appoints MPS Systems UK as Agent in United Kingdom
Trittau, Germany (July 18, 2013) – ROTOCONTROL, a manufacturer of leading-edge slitter/rewinder inspection machines today announced the appointment of MPS Systems UK as the ROTOCONTROL/LeoMat agent in the United Kingdom. MPS Systems UK, a subsidiary of the Dutch MPS Systems B.V., will now offer the ROTOCONTROL/LeoMat brand of leading-edge finishing machines for inspection, slitting, rewinding, die cutting, overprinting, digital labels and booklet labels for converters throughout the United Kingdom. Led by
Data8 to offer unlimited TPS, CTPS and MPS screening licences
Data8, the premier data enrichment specialist, have today announced that they will offer unlimited licenses to large volume TPS (Telephone Preference Service), CTPS (Corporate Telephone Preference Service) and MPS (Mail Preference Service) users. By removing the royalty fee structure, data8 believe it will encourage wide spread adoption by clients of these data files. Antony Allen, managing director data8, “I am pleased to announce today that from 1st February 2012 we